Benralizumab for the Prevention of COPD Exacerbations.

Gerard J CrinerBartolome R CelliChristopher E BrightlingAlvar AgustiAlberto PapiDave SinghDon D SinClaus F VogelmeierFrank C SciurbaMona BafadhelVibeke BackerMotokazu KatoAlejandra Ramírez-VenegasYu-Feng WeiLeif BjermerVivian H ShihMaria JisonSean O'QuinnNatalya MakulovaPaul NewboldMitchell GoldmanUbaldo J Martinnull nullnull null

Published in: The New England journal of medicine (2019)

Add-on benralizumab was not associated with a lower annualized rate of COPD exacerbations than placebo among patients with moderate to very severe COPD, a history of frequent moderate or severe exacerbations, and blood eosinophil counts of 220 per cubic millimeter or greater (Funded by AstraZeneca [GALATHEA and TERRANOVA] and Kyowa Hakko Kirin [GALATHEA]; GALATHEA and TERRANOVA ClinicalTrials.gov numbers, NCT02138916 and NCT02155660.).

Keyphrases

chronic obstructive pulmonary disease
lung function
cystic fibrosis
high intensity
early onset
randomized controlled trial
phase iii